基本信息
浏览量:163
职业迁徙
个人简介
I am a surgeon with special expertise in employing techniques that are minimally invasive for the treatment of urologic cancers, focusing on the novel management of prostate cancer, kidney tumors, and bladder cancer. During my MSK fellowship I received advanced training in focal therapies, which include a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its healthy tissue. I’ve also been involved in pioneering minimally invasive treatments for prostate cancer including robot-assisted procedures.
In addition, I have advanced skills in MRI-guided procedures for the diagnosis and treatment of prostate cancer and have performed more than 500 MRI-guided prostate biopsies. I’m also one of only a handful of surgeons experienced in doing extensive lymph node removals at the time of prostate surgery.
Committed to achieving cures while preserving quality of life, I am pioneering the development of a novel therapy for prostate cancer for men with less-advanced disease or tumors that are in only one area of the prostate. I’m currently the principal investigator in a clinical trial of a therapy called partial gland ablation that involves using precisely targeted ablative technology to treat only those areas containing prostate cancer cells. Preserving the remaining healthy gland allows physicians to deliver a treatment that is without side effects, such as incontinence or erectile dysfunction.
Dedicated to patient-centered care and eliminating the side effects associated with overtreatment of men with low-risk prostate cancer, I support the idea of active surveillance in men with low-risk disease. I am seeking to develop one of the largest surveillance clinics in the world, which includes both advanced imaging and the use of biomarkers to detect cancer progression.
I am an international expert in prostate cancer, and have done numerous invited presentations to academic medical centers and professional societies in the United States and around the world. In addition, I am a member of guideline committees that determine optimal prostate cancer management and work to improve prostate cancer biopsy outcomes.
I’ve published extensively, with more than 16 peer-reviewed studies. In addition, I serve on the editorial boards or am a reviewer on multiple prestigious journals including European Urology, Frontiers in Genitourinary Oncology, the Annals of Surgical Oncology, Cancer, and the British Journal of Urology International.
I am focused on serving my patients and their families and to offering integrated treatment plans tailored to each patient’s needs, concerns, and values.
Awards and Honors
Member, American Urological Association Core Curriculum Education Committee
Clinical Chair, Advanced Practice Pathology Program, College of American Pathologists
Administrative Chief Fellow, Memorial Sloan Kettering
Prostate Cancer Foundation Award – First Prize, Society of Urologic Oncology
Young Scientist Scholarship, University of Virginia School of Medicine
Alpha Omega Alpha, Honor Society, Georgetown University School of Medicine
In addition, I have advanced skills in MRI-guided procedures for the diagnosis and treatment of prostate cancer and have performed more than 500 MRI-guided prostate biopsies. I’m also one of only a handful of surgeons experienced in doing extensive lymph node removals at the time of prostate surgery.
Committed to achieving cures while preserving quality of life, I am pioneering the development of a novel therapy for prostate cancer for men with less-advanced disease or tumors that are in only one area of the prostate. I’m currently the principal investigator in a clinical trial of a therapy called partial gland ablation that involves using precisely targeted ablative technology to treat only those areas containing prostate cancer cells. Preserving the remaining healthy gland allows physicians to deliver a treatment that is without side effects, such as incontinence or erectile dysfunction.
Dedicated to patient-centered care and eliminating the side effects associated with overtreatment of men with low-risk prostate cancer, I support the idea of active surveillance in men with low-risk disease. I am seeking to develop one of the largest surveillance clinics in the world, which includes both advanced imaging and the use of biomarkers to detect cancer progression.
I am an international expert in prostate cancer, and have done numerous invited presentations to academic medical centers and professional societies in the United States and around the world. In addition, I am a member of guideline committees that determine optimal prostate cancer management and work to improve prostate cancer biopsy outcomes.
I’ve published extensively, with more than 16 peer-reviewed studies. In addition, I serve on the editorial boards or am a reviewer on multiple prestigious journals including European Urology, Frontiers in Genitourinary Oncology, the Annals of Surgical Oncology, Cancer, and the British Journal of Urology International.
I am focused on serving my patients and their families and to offering integrated treatment plans tailored to each patient’s needs, concerns, and values.
Awards and Honors
Member, American Urological Association Core Curriculum Education Committee
Clinical Chair, Advanced Practice Pathology Program, College of American Pathologists
Administrative Chief Fellow, Memorial Sloan Kettering
Prostate Cancer Foundation Award – First Prize, Society of Urologic Oncology
Young Scientist Scholarship, University of Virginia School of Medicine
Alpha Omega Alpha, Honor Society, Georgetown University School of Medicine
研究兴趣
论文共 265 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of Urologyno. 5S (2024)
Jonathan S. Fainberg,Behfar Ehdaie,Oguz Akin,Timothy Donahue,James Eastham, Connie Estes, Nicholas Fantanza,Samson Fine,Alvin Goh,Kwanghee Kim,Vincent Laudone, Nicole Liso,
Journal of Urologyno. 5S (2024)
European Urology (2024)
European urology (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn